OpenEvidence chief Daniel Nadler says he envisions changing the company’s ad-supported model, which has kept it free for medical professionals and driven its widespread adoption.

OpenEvidence chief Daniel Nadler says he envisions changing the company’s ad-supported model, which has kept it free for medical professionals and driven its widespread adoption.

65% of U.S. doctors reportedly use OpenEvidence, which is supported in part by pharmaceutical ads.